Let's Talk MRSA: 20 Frequently Asked Questions
By Vemco MedEd
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Vemco MedEd
Category: Education
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 20
Description
Designed to clarify persistent issues in serious MRSA infections that pose
a threat to patient safety and add to the healthcare burden. Experts answer frequently asked questions and share their own clinical experience. This activity consists of 20 episodes that will be released weekly beginning October 4, 2010.
| Episode | Date |
|---|---|
|
What are the short- and long-term challenges as well as advancements that will impact the management of patients with MRSA infections?
|
Feb 13, 2011 |
|
How can we prevent the spread of MRSA in the hospital?
|
Feb 06, 2011 |
|
Is there a role for OPAT in the management of patients with MRSA infections?
|
Jan 30, 2011 |
|
Can we determine the appropriate duration of therapy for MRSA infections?
|
Jan 23, 2011 |
|
What stewardship tactics can be applied to the management of MRSA infections?
|
Jan 16, 2011 |
|
Can we differentiate among newer agents for MRSA bacteremia and endocarditis?
|
Jan 09, 2011 |
|
How should clinicians manage MRSA bacteremia and infective endocarditis?
|
Jan 02, 2011 |
|
How can primary care physicians manage community-associated MRSA pneumonia?
|
Dec 26, 2010 |
|
What is the optimal treatment for MRSA nosocomial pneumonia?
|
Dec 19, 2010 |
|
What are the therapeutic options for a complicated skin or skin structure MRSA infection?
|
Dec 12, 2010 |
|
How can clinicians optimally manage community-associated MRSA skin infections?
|
Dec 05, 2010 |
|
What strategies can be used to effectively manage patients with skin and soft tissue MRSA infections?
|
Nov 28, 2010 |
|
When should an alternative agent to vancomycin be considered for MRSA infections?
|
Nov 21, 2010 |
|
What are the toxicity concerns associated with using vancomycin for MRSA infections?
|
Nov 14, 2010 |
|
Should therapeutic drug monitoring be considered when using vancomycin for MRSA infections?
|
Nov 07, 2010 |
|
What is the appropriate vancomycin dosing to maximize its effectiveness?
|
Oct 31, 2010 |
|
What is vancomycin 'MIC creep'?
|
Oct 24, 2010 |
|
What is community-associated MRSA? How is it different from healthcare-acquired MRSA?
|
Oct 17, 2010 |
|
Why is the prevalence of MRSA increasing in the hospital setting?
|
Oct 10, 2010 |
|
Why is MRSA such a problematic pathogen?
|
Sep 29, 2010 |